In this work, we propose a combination therapy strategy by co-applying a CSF1R inhibitor (BLZ945) and MHT to remodel the tumor immune microenvironment, yield the synergistic MHT-immunotherapy, and thus inhibit tumor growth and recurrence. The gene discussed is CSF1R; the disease is neoplasm.